相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab
Christopher Carlson et al.
ALZHEIMERS & DEMENTIA (2011)
Alzheimer's Association Report 2011 Alzheimer's disease facts and figures
ALZHEIMERS & DEMENTIA (2011)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
EHT0202 in Alzheimer's Disease: A 3-Month, Randomized, Placebo-Controlled, Double-Blind Study
B. Vellas et al.
CURRENT ALZHEIMER RESEARCH (2011)
Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads
Francesco Panza et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Solanezumab for Alzheimer's disease
Hossein Samadi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Antibody-based therapy in Alzheimer's disease
Refik Pul et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Therapeutic intervention for Alzheimer's disease with γγ-secretase inhibitors: still a viable option?
Bruno P. Imbimbo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Immunotherapy for Alzheimer's disease
D. Morgan
JOURNAL OF INTERNAL MEDICINE (2011)
Alzheimer's disease: clinical trials and drug development (vol 9, pg 702, 2010)
F. Mangialasche et al.
LANCET NEUROLOGY (2011)
Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
Susann Cattepoel et al.
PLOS ONE (2011)
Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration
Ming Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
Ronald S. Black et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2010)
Characterization of amino-terminally truncated Abeta-42 peptides in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment
Ronald B. DeMattos et al.
Alzheimers & Dementia (2010)
Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study
Taro Goto et al.
Alzheimers & Dementia (2010)
The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia
Jessica M. Mc Donald et al.
BRAIN (2010)
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Towards Disease-Modifying Treatment of Alzheimer's Disease: Drugs Targeting β-Amyloid
V. Frisardi et al.
CURRENT ALZHEIMER RESEARCH (2010)
Bapineuzumab
Geoffrey A. Kerchner et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease
Francesco Panza et al.
IMMUNOTHERAPY (2010)
PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Noel G. Faux et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Revising the definition of Alzheimer's disease: a new lexicon
Bruno Dubois et al.
LANCET NEUROLOGY (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Cynthia A. Lemere et al.
NATURE REVIEWS NEUROLOGY (2010)
Alzheimer's disease: clinical trials and drug development
Francesca Mangialasche et al.
LANCET NEUROLOGY (2010)
Identification, characterization, and comparison of amino-terminally truncated Aβ 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment
Ronald B. DeMattos et al.
Alzheimers & Dementia (2009)
Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo
Ryan J. Watts et al.
Alzheimers & Dementia (2009)
A γ-Secretase Inhibitor Decreases Amyloid-β Production in the Central Nervous System
Randall J. Bateman et al.
ANNALS OF NEUROLOGY (2009)
Quantitative and Mechanistic Studies of A beta Immunotherapy
Todd E. Golde et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2009)
Disease-Modifying Approach to the Treatment of Alzheimer's Disease From alpha-Secretase Activators to gamma-Secretase Inhibitors and Modulators
Francesco Panza et al.
DRUGS & AGING (2009)
Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?
Gregory A. Jicha
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ
Kaoru Yamada et al.
JOURNAL OF NEUROSCIENCE (2009)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (vol 7, pg 779, 2008)
L. Lannfelt et al.
LANCET NEUROLOGY (2009)
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Norman R. Relkin et al.
NEUROBIOLOGY OF AGING (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease
M. Britschgi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Vaccination in the elderly: an immunological perspective
Wilbur H. Chen et al.
TRENDS IN IMMUNOLOGY (2009)
S1-02-02: Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin
Norman R. Relkin
Alzheimers & Dementia (2008)
P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Eric R. Siemers et al.
Alzheimers & Dementia (2008)
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Dennis J. Selkoe
BEHAVIOURAL BRAIN RESEARCH (2008)
Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools
Peter Lichtlen et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Immunotherapy reduces vascular amyloid-β in PDAPP mice
Sally Schroeter et al.
JOURNAL OF NEUROSCIENCE (2008)
Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity:: Prevention by systemic passive immunization
Igor Klyubin et al.
JOURNAL OF NEUROSCIENCE (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Ganesh M. Shankar et al.
NATURE MEDICINE (2008)
Antibody capture of soluble A beta does not reduce cortical A beta amyloidosis in the PDAPP mouse
Peter Seubert et al.
NEURODEGENERATIVE DISEASES (2008)
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Scott A. Small et al.
NEURON (2008)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease:: a phase IIa, double-blind, randomised, placebo-controlled trial
Lars Lannfelt et al.
LANCET NEUROLOGY (2008)
Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway
Ganesh M. Shankar et al.
JOURNAL OF NEUROSCIENCE (2007)
A beta Oligomers - a decade of discovery
Dominic M. Walsh et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide
Gili Istrin et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
A specific amyloid-β protein assembly in the brain impairs memory
S Lesné et al.
NATURE (2006)
Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody
KR Bales et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice
EB Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Antibodies against β-amyloid reduce Aβ oligomers, glycogen synthase kinase-3β activation and τ phosphorylation in vivo and in vitro
QL Ma et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Effect of different anti-Aβ antibodies on Aβ fibrillogenesis as assessed by atomic force microscopy
J Legleiter et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease
RC Dodel et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity
YS Du et al.
BRAIN (2003)
Cerebral hemorrhage after passive anti-Aβ immunotherapy
M Pfeifer et al.
SCIENCE (2002)
Patients with Alzheimer disease have lower levels of serum antiamyloid peptide antibodies than healthy elderly individuals
ME Weksler et al.
EXPERIMENTAL GERONTOLOGY (2002)
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
JC Dodart et al.
NATURE NEUROSCIENCE (2002)
Brain to plasma amyloid-β efflux:: a measure of brain amyloid burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
SCIENCE (2002)
Phenotypic and functional changes in glial cells as a function of age
WH Yu et al.
NEUROBIOLOGY OF AGING (2002)
The cell biology of Alzheimer's disease: uncovering the secrets of secretases
J Walter et al.
CURRENT OPINION IN NEUROBIOLOGY (2001)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
分享论文
